Erythematosquamous Dermatosis
Introduction
Erythematosquamous dermatosis refers to a broad category of inflammatory skin conditions characterized by both redness (erythema) and scaling (squamae). These conditions often present with well-demarcated lesions that can vary in size, shape, and distribution across the body. Common examples include psoriasis, eczema, seborrheic dermatitis, and lichen planus, each with distinct clinical features but sharing the fundamental erythematous and squamous characteristics. These dermatoses are frequently chronic and can follow a relapsing-remitting course.
Biological Basis
The underlying biological basis of erythematosquamous dermatoses typically involves a complex interplay of genetic predispositions, immune system dysregulation, and environmental factors. At a cellular level, these conditions often manifest with abnormal keratinocyte proliferation and differentiation, leading to the characteristic scaling. Inflammation, mediated by various immune cells and cytokines, contributes to the redness and overall pathology. Genetic factors are known to play a significant role in susceptibility, influencing immune responses and skin barrier function. Environmental triggers, such as infections, stress, or certain medications, can often exacerbate or initiate symptoms in genetically predisposed individuals.
Clinical Relevance
From a clinical perspective, erythematosquamous dermatoses are highly relevant due to their widespread prevalence and significant impact on patient well-being. Patients often experience symptoms such as intense pruritus (itching), pain, discomfort, and visible skin lesions, which can lead to considerable physical and psychological distress. The chronic nature of many of these conditions necessitates long-term management strategies, including topical treatments, systemic medications, and phototherapy. Accurate diagnosis is crucial for effective treatment, as different erythematosquamous dermatoses require tailored therapeutic approaches. Complications can include secondary bacterial or fungal infections due to skin barrier disruption, and in some cases, systemic manifestations.
Social Importance
The social importance of erythematosquamous dermatoses stems from their impact on quality of life and public health. The visible nature of skin lesions can lead to stigmatization, reduced self-esteem, anxiety, and depression, affecting social interactions, relationships, and professional life. The chronic management of these conditions also imposes a substantial economic burden on individuals and healthcare systems through medication costs, doctor visits, and potential loss of productivity. Increased awareness, research into genetic underpinnings, and improved therapeutic options are vital for mitigating the individual and societal challenges posed by these common and often debilitating skin disorders.
Generalizability and Ancestral Diversity
The primary focus on the Taiwanese Han population, while providing invaluable insights for East Asian ancestries, inherently limits the direct generalizability of findings to other diverse populations. Research indicates that genetic architectures and the effect sizes of specific variants can differ significantly across ancestries, as demonstrated by discrepancies observed for variants like rs6546932 in the SELENOI gene between Taiwanese Han and European populations. [1] This population-specific genetic background necessitates tailoring polygenic risk score models to different ancestries to ensure their accuracy and clinical utility, thereby highlighting a critical challenge in applying findings broadly without further validation in diverse cohorts. Moreover, the underrepresentation of non-European populations in genetic studies generally hinders global research advancements and can exacerbate health disparities if genetic findings are predominantly applied based on data from a single ancestry. [1]
Phenotypic Characterization and Study Design Constraints
The study's reliance on electronic medical record (EMR) data collected from a single center, despite offering robust longitudinal follow-up, introduces potential cohort biases stemming from local clinical practices or specific population characteristics. Acknowledged limitations include the possibility of unrecorded comorbidities, which could lead to false-negative outcomes in case-control classifications, although the study suggests this impact was minimal due to the generally low prevalence of many diseases. [1] Furthermore, the predictive power of polygenic risk score models was observed to be directly correlated with cohort size [1] implying that for diseases with smaller participant numbers, the statistical power to identify robust associations or construct highly predictive models may have been constrained, affecting the certainty of results for less common conditions.
Complexity of Genetic Architecture and Environmental Factors
Understanding the genetic architecture of diseases is complicated by their multifactorial nature, often involving a complex interplay of numerous genes and environmental influences rather than single-gene causation. [1] While polygenic risk scores are designed to summarize cumulative genetic effects and can theoretically incorporate environmental factors, fully disentangling these intricate gene-environment interactions remains a significant challenge. The observation that for some polygenic risk score models, only demographic factors like age and sex showed significant effects, with no contributions from principal components, suggests that unmeasured environmental or lifestyle confounders might exert substantial, yet unquantified, influences on disease susceptibility. [1] Additionally, specific areas, such as the detailed associations between various HLA subtypes and diseases, require further comprehensive research, indicating persistent knowledge gaps in fully elucidating complex genetic contributions. [1]
Variants
Genetic variants play a crucial role in modulating immune responses and maintaining skin homeostasis, with specific single nucleotide polymorphisms (SNPs) contributing to susceptibility to erythematosquamous dermatosis, a group of inflammatory skin conditions characterized by redness and scaling. Variants such as rs12203592 in _IRF4_, rs12188300 near _IL12B_ and _LINC01845_, and rs12722496 and rs61839660 in _IL2RA_ are implicated in immune regulation. _IRF4_ (Interferon Regulatory Factor 4) is a transcription factor critical for the development and function of various immune cells, including T cells, B cells, and dendritic cells, influencing cytokine production and overall immune response. Variations in _IRF4_ can alter immune cell differentiation, potentially leading to dysregulated inflammation in the skin. _IL12B_ encodes a subunit of interleukin-12 and interleukin-23, key cytokines that drive T-helper 1 (Th1) and T-helper 17 (Th17) immune responses, both central to the pathogenesis of inflammatory skin diseases like psoriasis, a common form of erythematosquamous dermatosis. _LINC01845_, a long non-coding RNA, may regulate _IL12B_ expression, further influencing immune pathways. _IL2RA_ (Interleukin-2 Receptor Alpha) is vital for T-cell activation and immune tolerance; variants in this gene can impact T-cell responses and contribute to autoimmune conditions affecting the skin. The _ZMIZ1_ gene, with variant rs1250562, is involved in transcriptional regulation and has been linked to immune cell function and autoimmune diseases, underscoring the complex genetic landscape underlying these conditions. [1] The identification of disease-associated genetic variants through genome-wide association studies (GWAS) has been instrumental in understanding the genetic architecture of various complex traits, including those with dermatological manifestations. [1]
Skin barrier integrity and the regulation of proteases are fundamental to preventing inflammation and maintaining healthy skin. The _SPINK5_ gene, associated with rs7445392, encodes LEKTI, a crucial protease inhibitor that regulates epidermal desquamation and barrier function. Mutations in _SPINK5_ are known to cause Netherton syndrome, a severe erythematosquamous dermatosis, illustrating the profound impact of protease dysregulation on skin health. Milder variants can contribute to subtle defects in the skin barrier, increasing susceptibility to inflammation and environmental triggers. _PRSS22_ (Protease, Serine 22), located near _FLYWCH2_ with variant rs8046218, is another serine protease that may be involved in skin proteolysis and inflammatory processes, although its exact role in dermatosis is still being elucidated. Similarly, the _KLK6_ and _KLK7_ genes (Kallikrein-related Peptidases 6 and 7), linked by variant rs268890, encode proteases that are essential for the orderly shedding of skin cells and are implicated in inflammatory skin conditions when their activity is imbalanced. [1] Research into such genetic variations provides insight into the molecular mechanisms that underpin the development and progression of skin diseases. [1]
Beyond direct immune and barrier functions, other genetic factors contribute to the complex etiology of erythematosquamous dermatosis by influencing cellular signaling and antigen presentation. The _CARD14_ gene, with variant rs11150849, is a key component of the NF-κB signaling pathway, a central regulator of inflammation and immune responses. Strong associations between _CARD14_ mutations and psoriasis highlight its critical role in inflammatory skin conditions. _MC1R_ (Melanocortin 1 Receptor), associated with rs1805007, is primarily known for its role in pigmentation but also possesses anti-inflammatory properties in the skin, influencing how skin cells respond to environmental stressors and inflammation. Variants in _MC1R_ can alter the skin's inflammatory threshold and response to UV radiation. Lastly, _TAP2_ (Transporter 2, ATP Binding Cassette Subfamily B Member), associated with rs241454, is part of the major histocompatibility complex (MHC) class I antigen processing and presentation pathway, which is crucial for immune surveillance. Variations in _TAP2_ can affect the presentation of antigens to T cells, potentially contributing to the development of autoimmune diseases with skin manifestations. [1] The study of these diverse genetic factors, including those related to HLA, is essential for developing comprehensive polygenic risk models that can predict disease susceptibility and inform personalized treatment strategies for complex conditions like erythematosquamous dermatosis. [1]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs12203592 | IRF4 | Abnormality of skin pigmentation eye color hair color freckles progressive supranuclear palsy |
| rs12188300 | IL12B - LINC01845 | ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis psoriasis psoriatic arthritis psoriasis, type 2 diabetes mellitus psoriasis vulgaris |
| rs241454 | TAP2 | erythematosquamous dermatosis seborrheic dermatitis |
| rs1805007 | MC1R | Abnormality of skin pigmentation melanoma skin sensitivity to sun hair color freckles |
| rs11150849 | CARD14 | erythematosquamous dermatosis seborrheic dermatitis |
| rs8046218 | PRSS22 - FLYWCH2 | brain-specific serine protease 4 measurement seborrheic dermatitis erythematosquamous dermatosis |
| rs268890 | KLK6 - KLK7 | seborrheic dermatitis erythematosquamous dermatosis |
| rs7445392 | SPINK5 | erythematosquamous dermatosis |
| rs12722496 rs61839660 |
IL2RA | type 1 diabetes mellitus lymphocyte count erythematosquamous dermatosis seborrheic dermatitis |
| rs1250563 | ZMIZ1 | autoimmune thyroid disease, systemic lupus erythematosus, type 1 diabetes mellitus, ankylosing spondylitis, psoriasis, common variable immunodeficiency, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis erythematosquamous dermatosis seborrheic dermatitis |
Conceptual Frameworks for Dermatological Trait Identification
The identification and definition of dermatological conditions, like other medical traits, within large-scale genetic studies are fundamentally rooted in comprehensive clinical data captured over time. Research endeavors utilize Electronic Medical Records (EMRs) as a foundational dataset, which systematically document patient demographics, laboratory results, medical procedures, and diagnostic codes. This approach provides a rich, longitudinal view of an individual's health status, allowing for the precise ascertainment of various diseases based on multiple clinical encounters rather than single assessments or self-reported data. [1] The integration of deeply documented EMRs enhances data accuracy and disease classification, particularly for chronic and progressive conditions where diagnoses are often refined through repeated clinical visits. [1]
The nomenclature for diseases is standardized through established coding systems, which are critical for consistency in research and clinical practice. In studies leveraging extensive EMR data, diagnostic codes are primarily derived from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). These systems provide a hierarchical classification of diseases and health problems, ensuring a common language for medical record-keeping and epidemiological analysis. [1] The China Medical University Hospital (CMUH) specifically archives disease data using both ICD-9-CM and ICD-10-CM codes, with an automated conversion process in place to bridge the two classification versions, facilitating seamless data integration across different time periods. [1]
Standardized Classification and Diagnostic Criteria
For operational definition and precise diagnostic ascertainment in large cohort studies, the vast array of ICD codes is further consolidated into a more manageable and research-friendly system known as PheCodes. Initially, millions of ICD-9-CM and ICD-10-CM diagnostic codes are combined into a broader set of PheCodes, which are then refined based on data variation and participant numbers. This process resulted in a final categorization of 1085 distinct PheCodes used for subsequent genetic analyses, allowing for a standardized and consistent approach to phenotype definition across diverse traits. [1] These PheCodes serve as the primary operational definitions for categorizing participants into case and control groups for various disease associations.
The diagnostic criteria for establishing a medical diagnosis, including dermatological conditions, are stringently applied within these research frameworks to ensure robust case ascertainment. A key criterion involves the application of PheCode definitions on at least three distinct occasions for an individual to be classified as having a particular disease. This threshold minimizes misclassification and accounts for transient conditions or preliminary diagnoses, thereby increasing the reliability of disease phenotypes for genetic studies. [1] Such rigorous diagnostic and measurement approaches are vital for accurately identifying disease-associated genetic variants and calculating polygenic risk scores across a wide spectrum of human traits.
Clinical Presentation and Assessment Modalities
The clinical presentation of various conditions, including dermatoses, within the study cohort was systematically documented through comprehensive electronic medical records (EMRs). [1] These foundational datasets encompassed patient demographics, laboratory results, medical procedures, and diagnostic codes, which were meticulously recorded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and subsequently converted to ICD-10-CM. [1] Diagnoses were rigorously established following PheCode criteria, necessitating confirmation on at least three distinct occasions to ensure accuracy and minimize misclassification. [1] This reliance on physician-documented EMRs, rather than self-reported information, enhanced the precision of disease classification, particularly for chronic and progressive conditions where longitudinal follow-up (up to 19 years) allowed for refinement of diagnoses over time. [1]
Phenotypic Variability and Influencing Factors
Phenotypic diversity and variability in clinical features were significant considerations within the study's analysis of various traits. [1] Among the assessed clinical features, age and sex were identified as having significant effects on disease models. [1] The incidence of most diseases demonstrated an increase with advancing age, consistently showing a higher median age in case groups compared to control groups. [1] Furthermore, distinct gender ratios and sex differences were observed across various traits, indicating heterogeneity in how clinical presentations manifest between male and female participants. [1] These demographic and clinical correlations were integral to understanding the complex architecture of disease associations within the Taiwanese Han population. [1]
Diagnostic Significance and Predictive Modeling
The diagnostic value of clinical features, when combined with genetic insights, was evaluated using predictive models. [1] For various traits, combinations of clinical features and polygenic risk scores (PRS) demonstrated improved predictive accuracy, with some achieving Area Under the Curve (AUC) values exceeding 0.7. [1] While PRS alone had moderate predictive power (AUCs around 0.6 for some diseases), the integration of clinical features significantly bolstered the diagnostic utility of these models. [1] This approach highlights the importance of incorporating detailed clinical data, such as those derived from EMRs and PheCode classifications, for robust disease classification and identifying prognostic indicators, especially for conditions affecting multiple body systems. [1]
Causes
Erythematosquamous dermatosis, a condition affecting the integumentary system, arises from a complex interplay of genetic predispositions and various contributing factors. The understanding of its etiology often involves analyzing the cumulative effects of multiple genes and their interactions with an individual's broader physiological context.
Genetic Architecture and Polygenic Risk
Erythematosquamous dermatosis, as a dermatological trait, is characterized by a complex genetic architecture involving multiple genes. Studies indicate that conditions related to the integumentary system often exhibit a significant count of associated genes, suggesting a polygenic basis rather than being driven by a single genetic variant. [1] This complex interplay of numerous inherited variants collectively contributes to an individual's susceptibility, where the combined effect of these genes dictates the overall risk.
The cumulative impact of these genetic variants can be quantitatively assessed through polygenic risk scores (PRSs), which offer a comprehensive summary of disease susceptibility. [1] These scores integrate the contributions of various genetic markers, reflecting the intricate gene-gene interactions that underpin complex traits. Furthermore, an individual's unique genetic risk profile is significantly influenced by their ancestral background, underscoring the necessity for population-specific genetic studies to accurately characterize disease associations and develop targeted risk assessments. [1]
Broader Physiological and Demographic Influences
Beyond direct genetic predispositions, the manifestation and progression of dermatological conditions like erythematosquamous dermatosis can be influenced by broader physiological and demographic factors. Age is a notable contributor, as research generally indicates that the incidence of many diseases tends to increase with advancing age. [1] This suggests age-related physiological changes may modulate disease risk or severity.
Similarly, sex can play a role in disease prevalence and presentation. Certain traits exhibit distinct gender ratios or are observed predominantly in one sex, indicating potential hormonal, genetic, or environmental differences between sexes that influence disease susceptibility. [1] While specific comorbidities for erythematosquamous dermatosis are not detailed, the presence of other systemic conditions could potentially modify its course or presentation, reflecting the interconnectedness of various bodily systems.
Interplay of Genetic and Environmental Factors
The development of complex dermatological conditions, including erythematosquamous dermatosis, is understood to arise from an intricate interplay between an individual's genetic predisposition and various environmental factors. Diseases generally result from the combined influence of both inherited genetic traits and external elements. [1] This highlights that while genetics may confer susceptibility, environmental triggers or exposures can often play a crucial role in disease onset or exacerbation.
Polygenic risk scores are designed to integrate these environmental considerations into their predictive models, providing a more comprehensive understanding of disease susceptibility that extends beyond genetic factors alone. [1] Although specific environmental factors such as lifestyle, diet, exposure, socioeconomic status, or geographic influences are not detailed for erythematosquamous dermatosis in the available research, their general importance in complex disease etiology suggests they likely contribute to the overall risk profile.
The provided research context does not contain specific information about 'erythematosquamous dermatosis'. Therefore, a biological background section for this trait cannot be generated based solely on the given material.
Large-scale Cohort Studies and Longitudinal Observations
The understanding of population-level disease patterns is significantly advanced by large-scale cohort studies that integrate extensive clinical and genetic data. The HiGenome cohort, established in 2018 in Taiwan, exemplifies this approach, enrolling 323,397 participants of East Asian (EAS) ancestry from across highly populated towns and districts. [1] This cohort leverages electronic medical records (EMRs) from China Medical University Hospital (CMUH) spanning from 2003 to 2021, providing up to 19 years of longitudinal follow-up for a substantial portion of participants, with 27.9% followed for over 15 years. [1] This long-term data collection is crucial for observing temporal patterns of disease incidence and progression across a broad age range, from 0 to 111 years. [1] The HiGenome project aims to elucidate the genetic predisposition to common diseases within the Taiwanese Han population, facilitating improved prediction and prevention strategies. [1]
The deep integration of physician-documented EMRs, rather than relying on self-reported data, enhances the accuracy of disease classification and clinical phenotyping, particularly for chronic conditions that require multiple clinical visits for diagnosis refinement. [1] This methodology contrasts with other major biobanks like UK Biobank (UKBB) and FinnGen, which often incorporate self-reported information susceptible to recall bias, thereby positioning HiGenome as a robust resource for genetic and epidemiological research in an EAS population. [1] Furthermore, the hospital-based design enables continuous follow-up and the ongoing expansion of longitudinal data, supporting comprehensive studies on disease progression and associated factors. [1]
Epidemiological Patterns and Demographic Associations
Epidemiological analyses within such large cohorts reveal critical demographic associations and prevalence patterns for various health conditions. In the HiGenome cohort, the male-to-female ratio was 45.3:54.7, with the mean age of male participants slightly higher than females. [1] A consistent finding across most diseases analyzed was an increase in incidence with age and time, with disease groups generally exhibiting a higher median age compared to control groups. [1] While the overall gender distribution in the control group was relatively consistent, specific traits showed notable disparities in gender proportions within the case groups, highlighting sex-specific epidemiological influences on disease presentation. [1]
The extensive EMR data allowed for the categorization of participants into case and control groups based on 1085 phenotypes using PheCode criteria, with diagnoses established on at least three distinct occasions. [1] Diagnostic instances within the CMUH system grew significantly, from 800,000 in 2003 to approximately 7 million by 2021, reflecting a substantial volume of clinical data available for analysis. [1] Patients primarily sought treatment for conditions affecting the circulatory, endocrine, metabolic, genitourinary, and digestive systems, indicating the major health burdens within this population. [1]
Cross-Population Comparisons and Ancestry Considerations
Understanding disease etiology requires careful consideration of ancestry and geographic variations, as genetic risk factors are often influenced by population-specific lineages. The HiGenome cohort specifically targets the Taiwanese Han population, ensuring a focused genetic dataset for East Asian individuals. [1] Ancestry analysis confirmed that the majority of participants were consistent with EAS individuals, predominantly mapping to Southern Han Chinese lineages, followed by Han Chinese from Beijing, Chinese Dai, Kinh from Vietnam, and Japanese individuals. [1] A small subset also showed resemblance to individuals of Northern or Western European ancestry. [1]
This specific focus on a well-defined EAS population provides valuable insights into genetic architectures that may differ from those observed in predominantly European cohorts, such as UKBB or MVP. [1] The inclusion of individuals with mixed EAS descent, alongside the predominant ancestral lineages, allows for robust genetic analyses with appropriate principal component adjustments to account for population structure. [1] Such cross-population comparisons are vital for identifying rare variants with higher minor allele frequencies in specific populations and for assessing the generalizability of polygenic risk scores and genetic associations across diverse ethnic groups. [1]
Methodological Framework and Data Strengths
The robust methodologies employed in population studies are crucial for the reliability and generalizability of findings. The HiGenome study utilized a comprehensive approach, extracting genotypic data from blood samples using an Affymetrix Axiom genotyping platform, specifically a custom Axiom TPMv1 SNP array, and enhancing it with imputation algorithms to expand the dataset to nearly 14 million reference points. [1] Phenotypic data were meticulously collected from EMRs, matched with relevant PheCodes for consistent disease classification, requiring diagnoses to be established on at least three distinct occasions to ensure accuracy. [1] This approach formed the basis for conducting genome-wide association studies (GWASs) and phenome-wide association studies (PheWASs) to explore disease-gene associations. [1]
Key strengths of the HiGenome methodology include its reliance on detailed physician-documented EMRs, which minimizes recall bias often associated with self-reported data in other large cohorts. [1] The extensive longitudinal follow-up period, combined with a significant proportion of participants under 45 years of age, offers unique opportunities to study disease onset and progression across different life stages. [1] Rigorous quality control measures were applied to genetic data, including exclusions for related individuals, low call rates, Hardy-Weinberg equilibrium deviations, and minor allele frequency thresholds, ensuring the integrity of subsequent genetic analyses. [1]
Frequently Asked Questions About Erythematosquamous Dermatosis
These questions address the most important and specific aspects of erythematosquamous dermatosis based on current genetic research.
1. My mom has this skin problem. Will I get it too?
Yes, there's a good chance of genetic predisposition. Your genes play a significant role in how susceptible you are to these inflammatory skin conditions, influencing immune responses and skin barrier function. Variants in genes like IRF4 or IL12B, which are crucial for immune regulation, can be passed down, increasing your likelihood of developing a similar condition.
2. Does stress really make my skin flare up?
Yes, it absolutely can. Stress is a known environmental trigger that can exacerbate or even initiate symptoms in individuals who are genetically predisposed. Your genetic makeup, including variations in genes that regulate immune cells and inflammation, can influence how your immune system reacts to stress, leading to dysregulated responses in your skin.
3. I get sick often; does that make my skin worse?
It's possible, yes. Infections are a common environmental trigger for these skin conditions. If you have a genetic predisposition, for instance, variations in genes like IL12B that drive immune responses, your immune system might overreact to infections, contributing to the inflammation and scaling characteristic of erythematosquamous dermatosis.
4. I'm not from Taiwan; does my background change my risk?
Yes, your ancestry can matter. Research indicates that genetic risk factors and their effect sizes can differ significantly across diverse populations, as seen with variants like rs6546932 in the SELENOI gene. This means your specific genetic background could influence your unique risk profile for these conditions compared to other ancestries.
5. Can certain medicines trigger my skin problem?
Yes, they can. Some medications are known environmental triggers that can initiate or worsen symptoms in people with a genetic susceptibility. Your individual genetic profile, influencing your immune system and how your body processes substances, might determine how you react to certain drugs, potentially leading to a flare-up of your skin condition.
6. Why does my skin condition keep coming back?
The chronic and relapsing-remitting nature of these conditions is often tied to your genetic makeup. Your genes influence your immune system's regulation and skin cell behavior, making you prone to ongoing or recurring inflammation and abnormal skin cell growth, which contribute to the persistence of the condition.
7. My skin makes me really self-conscious. Is that normal?
Absolutely. The visible nature of these skin lesions, which stem from genetically influenced inflammation and scaling, can significantly impact self-esteem. It's common for people with these conditions to experience anxiety, depression, and social distress because of how their skin looks and the potential for stigmatization.
8. Can my skin problem lead to other health issues?
Yes, it can. Your skin's barrier function can be compromised due to the underlying inflammation and abnormal cell growth, which has a genetic component. This makes you more susceptible to secondary bacterial or fungal infections, and in some cases, these conditions can even have systemic effects on your body beyond the skin.
9. Would a DNA test tell me if I'm at risk?
Potentially, yes. Genetic studies are identifying specific variants, such as those in IL2RA or ZMIZ1, that contribute to susceptibility. A DNA test could help assess your polygenic risk score, which summarizes your cumulative genetic predisposition, though these models require further validation for diverse populations.
10. My sibling has clear skin, but I don't. Why the difference?
Even with shared parents, you and your sibling inherit unique combinations of genetic variants that influence your immune system and skin. While there's a general genetic predisposition for these conditions, subtle differences in these inherited genes, along with individual environmental exposures, can lead to one sibling developing symptoms and the other not.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Liu TY et al. Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. Sci Adv. 2025;11:eadt0539